Hanson wade have taken the decision to cancel this meeting.
Please do accept our apologies for any inconvenience or disappointment this will cause.

Please register your interest here if you would like updates on the meeting or topic.

19876 CTfD Homepage Banner

Transform the Clinical to Commercial Development of Diabetes Cell Therapies

Diabetes is a chronic disorder with a huge unmet medical need, currently treatments aim to manage symptoms however these are expensive and time consuming for patients and healthcare systems, resulting in huge cost burdens and poor quality of life.

The Cell Therapy for Diabetes Digital Consortium will enable you to harness the clinical to commercial development of diabetes cell therapies through ensuring the engraftment of cells to host site, preventing immune activation and clearance and achieving scalable manufacturing to change patients’ lives.

Through the shared learnings and experiences of the fields brightest minds we will aim to bring you a platform to discuss the biggest obstacles to accelerating to market cell therapies for diabetes.

We gather the global leaders in diabetes, stem cell, autoimmune and beta cell replacement therapies as we improve the delivery, quality and scalability of cell therapies to transform the clinical to commercial development
of diabetes cell therapies
for patients in need.

Learn about the latest innovations in gene editing and engineering technologies alongside how to overcome the nitty gritty in process and analytical development. Join us for series of digital working groups to delve into the key challenges
in this space and identify tangible solutions to takeaway.

At a time when we are more isolated than ever, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of cell therapies for diabetes.

Upcoming Digital Working Groups

Join us for a series of digital working groups to delve into the key challenges in this space and identify tangible solutions.

Delivery of Cell Therapies in Diabetes: Encapsulation and Beyond

Preventing alloreactivity of engrafted cells for treatment in diabetes is of utmost importance to ensure efficacy and durability of treatment. Encapsulation methods and the utilization of medical devices allows cells to be able to do this, however, the techniques and technologies are vast and varied.

Scalable Manufacturing for Cell Therapies in Diabetes

Manufacturing of cells is complex, labour intensive and costly. As we aim to scale up our efforts to meet commercial demand these factors become prohibitive for successful delivery and uptake of life-changing therapies.

Cell and Gene Therapy Approaches for Diabetes

From the advent of CRISPR technologies to the approval of CAR engineered technologies, gene engineering and editing is all the rage as these approaches show success in treating and curing patients.

As cell and gene therapies advance many of these innovations are being utilised in the journey to finding curative treatments for diabetes.

What is the Digital Consortium?

A series of virtual working groups that come together to harness the collective power of the industry’s “brain trust”.

We all know drug development rarely happens in isolation there is a need for a multitude of stakeholders to carry their weight and ensure the successful discovery, translation, and commercialization of therapeutics from bench to bedside.

Working with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of cell therapies for diabetes to bring you the opportunity to share invaluable insights, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of cell therapies for diabetes.

At a time when we are more isolated than ever, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of cell therapies for diabetes.